MIRAGEN THERAPEUTICS, INC. (48)

Browse by Contract Category

Contracts

Underwriting Agreement by and among the Company and the Representatives, dated as of September 20, 2021 (Filed With SEC on September 23, 2021)
Fifth Addendum to Lease by and between Registrant and Crestview, LLC, dated as of March 26, 2021 (Filed With SEC on August 12, 2021)
Open Market Sale Agreement (Filed With SEC on August 12, 2021)
Kristian Humer Employment Agreement, dated June 9, 2021 (Filed With SEC on July 26, 2021)
Technology License Agreement, by and between the Registrant and Xencor, Inc., dated as of December 16, 2020 (Filed With SEC on March 26, 2021)
Agreement and Plan of Merger, dated October 27, 2020, by and among Miragen Therapeutics, Inc., Oculus Merger Sub I, Inc., Oculus Merger Sub II, LLC and Viridian Therapeutics, Inc (Filed With SEC on October 28, 2020)
Eighth Amendment of the License and Collaboration Agreement, entered into as of January 21, 2019 and effective as of January 7, 2019, by and between Registrant and Les... (Filed With SEC on March 14, 2019)
Fifth Addendum to Lease by and between Registrant and Crestview, LLC, dated as of March 26, 2021 (Filed With SEC on May 7, 2021)
Consulting Agreement, dated as of February 1, 2021, by and between the Registrant and William S. Marshall, Ph.D (Filed With SEC on May 7, 2021)
Open Market Sale Agreement, dated April 23, 2021, by and between Viridian Therapeutics, Inc. and Jefferies LLC (Filed With SEC on April 26, 2021)
Subscription Agreement, by and between the Registrant and Xencor, Inc., dated as of December 16, 2020 (Filed With SEC on March 26, 2021)
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 26, 2021)
Employment Agreement by and between the Registrant and Barrett Katz, M.D., dated as of January 18, 2021 (Filed With SEC on March 26, 2021)
Separation and Release Agreement, dated as of September 27, 2020 by and between the Registrant and Diana Escolar, M.D (Filed With SEC on March 26, 2021)
Amended and Restated 2016 Equity Incentive Plan (Filed With SEC on March 26, 2021)
Form of 2020 Incentive Stock Option Grant Notice under Viridian Therapeutics, Inc. 2020 Stock Incentive Plan (Filed With SEC on March 26, 2021)
Separation and Release Agreement by and between the Company and Lee Rauch, dated as of January 15, 2020 (Filed With SEC on January 20, 2021)
Employment Agreement by and between the Company and Jonathan Violin, dated as of January 15, 2021 (Filed With SEC on January 20, 2021)
License Agreement, by and between the Company and ImmunoGen, dated as of October 12, 2020 (Filed With SEC on December 9, 2020)
Registration Rights Agreement, dated as of October 30, 2020, by and among the Registrant and certain purchasers (Filed With SEC on November 12, 2020)
Bonus Agreement, dated as of September 14, 2020, by and between the Registrant and Jason Leverone (Filed With SEC on November 12, 2020)
Consulting Agreement, dated as of October 16, 2020, by and between the Registrant and William S. Marshall, Ph.D (Filed With SEC on November 12, 2020)
Separation Agreement, dated as of October 15, 2020, by and between the Registrant and William S. Marshall, Ph.D (Filed With SEC on November 12, 2020)
Amendment to Research Subaward Agreement, entered into as of August 11, 2020, by and between Registrant and Yale University (Filed With SEC on November 12, 2020)
Form of Registration Rights Agreement, by and among Miragen Therapeutics, Inc. and certain purchasers (Filed With SEC on October 28, 2020)
Securities Purchase Agreement, dated as of October 27, 2020, by and among Miragen Therapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on October 28, 2020)
Bonus Agreement, dated as of September 27, 2020, by and between the Company and Diana Escolar, M.D (Filed With SEC on October 1, 2020)
Form of Bonus Agreement, dated as of September 14, 2020, by and between the Company and Diana Escolar, M.D (Filed With SEC on September 17, 2020)
Form of Bonus Agreement, dated as of September 14, 2020, by and between the Company and Jason Leverone (Filed With SEC on September 17, 2020)
Amended and Restated Employment Agreement, dated as of September 14, 2020, by and between the Company and Lee Rauch (Filed With SEC on September 17, 2020)
Form of Consulting Agreement, dated as of September 14, 2020, by and between the Company and William S. Marshall, Ph.D (Filed With SEC on September 17, 2020)
Form of Separation Agreement, dated as of September 14, 2020, by and between the Company and William S. Marshall, Ph.D (Filed With SEC on September 17, 2020)
Employment Agreement by and between the Registrant and Lee Rauch, dated as of June 16, 2020 (Filed With SEC on June 19, 2020)
Fourth Addendum to Lease by and between Registrant and Crestview, LLC, dated as of April 7, 2020 (Filed With SEC on May 8, 2020)
Deferral Agreement between Silicon Valley Bank and the Registrant effective as of April 6, 2020 (Filed With SEC on May 8, 2020)
Amendment to Research Subaward Agreement, entered into as of April 7, 2020, by and between Registrant and Yale University (Filed With SEC on May 8, 2020)
U.S. Small Business Administration Paycheck Protection Program Note, by and between Miragen Therapeutics, Inc. and Silicon Valley Bank, dated April 21, 2020 (Filed With SEC on April 27, 2020)
Third Addendum to Lease by and between Registrant and Crestview, LLC, dated as of January 17, 2020 (Filed With SEC on March 13, 2020)
Employment Agreement by and between the Registrant and Diana Escolar, M.D., dated as of February 20, 2020 (Filed With SEC on March 13, 2020)
Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 13, 2020)
Form of Warrant to Purchase Common Stock (Filed With SEC on February 7, 2020)
Underwriting Agreement, dated February 7, 2020, by and among Miragen Therapeutics, Inc. and Oppenheimer & Co. Inc (Filed With SEC on February 7, 2020)
Common Stock Purchase Agreement, dated December 11, 2019 between Miragen Therapeutics, Inc. and Aspire Capital Fund, LLC (Filed With SEC on December 11, 2019)
Registration Rights Agreement, dated December 11, 2019, between Miragen Therapeutics, Inc. and Aspire Capital Fund, LLC (Filed With SEC on December 11, 2019)
Amendment No. 1 to Amended and Restated License Agreement, effective as of August 8, 2019, by and between Registrant and Roche Innovation Center Copenhagen A/S (Filed With SEC on November 8, 2019)
Amendment to Research Subaward Agreement, entered into as of October 11, 2019 and effective as of August 12, 2019, by and between Registrant and Yale University, as amended (Filed With SEC on November 8, 2019)
Assignment and Assumption Agreement, dated as of October 28, 2019, by and between the Registrant, The Leukemia & Lymphoma Society, Inc. and LLS TAP Miragen, LLC (Filed With SEC on October 31, 2019)
Amendment to Research Subaward Agreement, entered into as of March 7, 2019 and effective as of September 1, 2018, by and between Registrant and Yale University, as amended (Filed With SEC on May 9, 2019)